KV Readies For End-Of-March Makena Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Born-again women's specialty pharma renegotiates debt, completes $32 million PIPE, hires 95 new sales reps and sets up a dedicated customer support center for the newly approved drug to prevent preterm birth.
You may also be interested in...
FDA Steps Into Makena Pricing Dispute In The Name Of "Access"
FDA is citing patient access as the reason behind its unusual decision to insert itself in the middle of a pricing debate involving KV Pharmaceuticals’ pre-term delivery drug Makena.
FDA Steps Into Makena Pricing Dispute In The Name Of "Access"
FDA is citing patient access as the reason behind its unusual decision to insert itself in the middle of a pricing debate involving KV Pharmaceuticals’ pre-term delivery drug Makena.
Makena Pricing Prompts Multi-Pronged Appeals: FDA, FTC – Bayh-Dole?
The uproar among insurers, physicians and patient groups over the relatively high price of KV Pharmaceutical’s new injectable treatment for preventing preterm births, Makena, has elicited appeals to FDA and the Federal Trade Commission for intervention.